Drugs / PF-05280014
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02015156 | Jan → Feb 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01603264 | May → Dec 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02187744 | Sep 2014 → Mar 2016 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01989676 | Feb 2014 → Aug 2016 | breast cancer | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-09-09 | Pfizer | Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin® (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress pfizer.com ↗ |
| 2016-11-30 | Pfizer | Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab) pfizer.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-05280014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01603264 ↗ |
| Known as | Trastuzumab-Pfizer | “The current study will compare PK, efficacy, safety, and immunogenicity of PF-05280014 (Trastuzumab-Pfizer) in combination with Taxotere® and Carboplatin (Paraplatin) versus...” NCT02187744 ↗ |
| Route | Intravenous | “single intravenous administration” NCT01603264 ↗ |